{"entity":{"id":"luca-gianni","kind":"person","name":"Luca Gianni","aka":[],"tldr":"Milan oncologist who led NeoSphere, the trial that showed adding pertuzumab to trastuzumab and docetaxel before surgery clears more HER2-positive breast cancers, the basis for pertuzumab's neoadjuvant approval.","summary":"Luca Gianni led medical oncology at the Istituto Nazionale dei Tumori and then at San Raffaele Hospital in Milan, and now leads the Fondazione Michelangelo. He was first author of the 2012 Lancet Oncology report of NeoSphere, the phase 2 trial in which pertuzumab plus trastuzumab and docetaxel produced a higher pathological complete response rate than trastuzumab and docetaxel, and of the NOAH trial of neoadjuvant trastuzumab. His trials helped establish pathological complete response as an endpoint for accelerated approval.","asOf":"2026-09-18","links":[],"tags":["breast","neoadjuvant","trialist"],"related":[],"cancers":["her2-positive-early-breast-cancer","breast-her2-positive"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["fondazione-michelangelo"],"pathways":[],"terms":[],"trials":["neosphere"],"people":[],"bottlenecks":[],"keyPapers":["paper-luca-gianni-j-clin-oncol-2022","paper-luca-gianni-cancer-med-2023","paper-luca-gianni-j-natl-cancer-inst-2022"],"journals":[],"dependsOn":[],"notes":[],"role":"Medical oncologist and President, Fondazione Michelangelo, Milan","institutionId":"fondazione-michelangelo","specialisms":["HER2-positive breast cancer","Neoadjuvant therapy","Pathological complete response"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Gianni%5BAuthor%5D"}],"papers":[{"title":"Trastuzumab Emtansine Plus Pertuzumab Versus Taxane Plus Trastuzumab Plus Pertuzumab After Anthracycline for High-Risk Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer: The Phase III KAITLIN Study","journal":"Journal of Clinical Oncology","year":2022,"url":"https://doi.org/10.1200/jco.21.00896","doi":"10.1200/jco.21.00896","note":"Europe PMC author record matched by affiliation (Fondazione Michelangelo); 68 citations on Europe PMC."},{"title":"Phase II study (KAMELEON) of single-agent T-DM1 in patients with HER2-positive advanced urothelial bladder cancer or pancreatic cancer/cholangiocarcinoma","journal":"Cancer medicine","year":2023,"url":"https://doi.org/10.1002/cam4.5893","doi":"10.1002/cam4.5893","note":"Europe PMC author record matched by affiliation (Fondazione Michelangelo); 50 citations on Europe PMC."},{"title":"Predictive Role of CD36 Expression in HER2-Positive Breast Cancer Patients Receiving Neoadjuvant Trastuzumab","journal":"JNCI: Journal of the National Cancer Institute","year":2022,"url":"https://doi.org/10.1093/jnci/djac126","doi":"10.1093/jnci/djac126","note":"Europe PMC author record matched by affiliation (Fondazione Michelangelo); 30 citations on Europe PMC."}],"orcid":"0000-0002-2372-9625"},"route":"/people/luca-gianni/","neighbours":{"cancer":[{"id":"her2-positive-early-breast-cancer","kind":"cancer","name":"Early HER2-positive breast cancer","route":"/cancers/her2-positive-early-breast-cancer/"},{"id":"breast-her2-positive","kind":"cancer","name":"HER2-positive breast cancer","route":"/cancers/breast-her2-positive/"}],"institution":[{"id":"fondazione-michelangelo","kind":"institution","name":"Fondazione Michelangelo","route":"/institutions/fondazione-michelangelo/"}],"trial":[{"id":"neosphere","kind":"trial","name":"NeoSphere","route":"/trials/neosphere/"}],"paper":[{"id":"paper-luca-gianni-cancer-med-2023","kind":"paper","name":"Phase II study (KAMELEON) of single-agent T-DM1 in patients with HER2-positive advanced urothelial bladder cancer or pancreatic cancer/cholangiocarcinoma","route":"/key-papers/paper-luca-gianni-cancer-med-2023/"},{"id":"paper-luca-gianni-j-natl-cancer-inst-2022","kind":"paper","name":"Predictive Role of CD36 Expression in HER2-Positive Breast Cancer Patients Receiving Neoadjuvant Trastuzumab","route":"/key-papers/paper-luca-gianni-j-natl-cancer-inst-2022/"},{"id":"paper-luca-gianni-j-clin-oncol-2022","kind":"paper","name":"Trastuzumab Emtansine Plus Pertuzumab Versus Taxane Plus Trastuzumab Plus Pertuzumab After Anthracycline for High-Risk Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer: The Phase III KAITLIN Study","route":"/key-papers/paper-luca-gianni-j-clin-oncol-2022/"}]}}